1.53

0.00% +0.00

Aethlon Medical Inc (AEMD)

Overview News Price History Discussions Forecast Stock Split

Aethlon Medical Inc stock is currently priced at $1.53, with a 24-hour trading volume of 356. It has seen a +0.00% increased in the last 24 hours and a -12.07% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.52 pivot point. If it approaches the $1.54 resistance level, significant changes may occur.

Previous Close:

$1.53

Open:

$1.5018

24h Volume:

356

Market Cap:

$3.95M

Revenue:

$294.20K

Net Income/Loss:

$-12.25M

P/E Ratio:

-0.2782

EPS:

-5.5

Net Cash Flow:

$-10.77M

1W Performance:

+8.13%

1M Performance:

-12.07%

6M Performance:

+2.68%

1Y Performance:

+240.00%

1D Range:

$1.5018

$1.503

52W Range:

$0.195

$2.3499

Aethlon Medical Inc Stock (AEMD) Company Profile

Name

Aethlon Medical Inc

Sector

Healthcare (1201)

Industry

Medical Devices (158)

Phone

619 941 0360

Address

11555 Sorrento Valley Road, Suite 203, San Diego, CA

Employee

Twitter

@Aethlon_Medical

Next Earnings Date

2024-02-14

Latest SEC Filings

AEMD's Discussions on Twitter

Aethlon Medical Inc Stock (AEMD) Latest News

Why Faraday Future Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Benzinga

Aethlon Medical Inc Stock (AEMD) Financials Data

Aethlon Medical Inc (AEMD) Revenue 2024

AEMD reported a revenue (TTM) of $294.20 thousand for the quarter ending March 31, 2022.

Aethlon Medical Inc (AEMD) Net Income 2024

AEMD net income (TTM) was -$12.25 million for the quarter ending December 31, 2023, a +8.23% increase year-over-year.

Aethlon Medical Inc (AEMD) Cash Flow 2024

AEMD recorded a free cash flow (TTM) of -$10.77 million for the quarter ending December 31, 2023, a +8.76% increase year-over-year.

Aethlon Medical Inc (AEMD) Earnings per Share 2024

AEMD earnings per share (TTM) was -$5.05 for the quarter ending December 31, 2023, a +32.49% growth year-over-year.

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.